Our group studies the molecular mechanisms involved in chronic retinal diseases with the aim of developing new genetic and pharmacological therapeutic strategies
The Retinal Pigment Epithelium (RPE) is a highly specialized layer of cells, representing a fundamental component of the visual unit. In many retinal disorders, photoreceptor degeneration occurs as a consequence of RPE dysfunction.
Our group combines expertise in retinal cell biology, both in normal and pathological conditions. For the latter, we have focused our studies on Choroideremia, an X-linked form of retinal degeneration. We are now extending our studies to dissect the role of the RPE in AMD. Furthermore, we are using differentiation methods to derive RPE from human ES and iPS cells. Our RPE in vitro system will be used for fundamental studies as well as for potential translational applications to treat retinal degeneration.
Diabetic retinopathy is a complication of diabetes and a leading cause of vision loss in the working age population worldwide. There are no effective treatments for preventing DR onset or progression to severe late stages. Our goal is to develop new genetic and pharmacological therapeutic strategies to overcome syn loss of function and gain of toxic function, taking advantage of the privileged status of the eye for both therapies.
Microfluidic Device Intergrading a Selectively Permeable Membrane and a 3D Vascular Network for the In Vitro Development of Anatomical-functional Barrier
Three-Dimensional Model of Early Diabetic Retinopathy
Pursuant to the provisions of article 11, paragraph 2, of Decree-Law no. 57/2016, of August 29, it becomes public that by Dean’s decree of February 10, 2022, the opening of an international selection competition procedure was authorized for the completion of a PhD holder job vacancy for the exercise of scientific research activities financed by the Programa Operacional Regional de Lisboa in its FEDER component and by the Fundação para a Ciência e Tecnologia in its national component, under an uncertain fixed-term employment contract under the Labor Code in the Faculdade de Ciências Médicas|NOVA Medical School, Universidade NOVA de Lisboa.
Application deadline: March 25th 2022
Deadline for contact: 17th March 2023
Research carried out by several of our laboratories is supported by the LYSOCIL project and has been published in Traffic magazine.
The final conference of the LYSOCIL project took place on the 8th and 9th of April at the Hotel Vila Galé in Cascais. It featured presentations from the various project partners and collaborators worldwide, including Italy and Germany.
Five researchers from NOVA Medical School are part of the ranking of Elsevier, one of the most recognized publishers of scientific publications.
To observe the Brain Awareness Week, NMS organized two neuroscience fairs in two schools in Lisbon and one "pop-up" science center at Museu da Saúde, between March 13th and 17th.
NOVA Medical SchoolCampo Mártires da Pátria, 1301169-056 LisboaPORTUGAL
GeneralTel.: +351 218 803 000
Compliment, suggestion or complaint
News and Events
Awards and Honours